A new mouse model of experimental melanoma for vaccine and lymphokine therapy

International Journal of Oncology

Volumn 13, Issue 2, 1998, Pages 361-374

  Shrayer, David P ^a,d   Bogaars, Hendrix ^a   Wolf, Stanley F ^b   Hearing, Vincent J ^c   Wanebo, Harold J ^a  

^a BROWN UNIVERSITY   (United States)

^b MS 35 1127   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

Immunization; Melanoma; Monovalent antigen; Polyclonal antibody; Polyvalent antigen

Indexed keywords

CYTOTOXIC ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOKINE; MELANOMA ANTIGEN; MELANOMA VACCINE; MESSENGER RNA; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BONE MARROW METASTASIS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; IMMUNOGENICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION; VACCINE PRODUCTION;

EID: 0031817896     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.2.361     Document Type: Article

References (96)

1. Greens EL (ed): Characteristic tumors. In: Handbook on Genetically Standardized JAX Mice. Mc-Graw-Hill, New York, pp521-562, 1977.
2. Berkelhammer J, Oxenhandler RW, Hook RR and Hennessey JM: Development of a new melanoma model in C57BL/6 mice. Cancer Res 42: 3157-3163, 1982.
3. Fidler IJ and Hart IR: Host immunity in experimental metastasis. In: Immunological Aspects of Cancer. Castro J (ed). Lancaster MTD Press, pp 183-204, 1978.
4. Platt D and Raz A: Modulation of the lung colonization of B 16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst 84: 438-442, 1992.
5. Fidler IJ and Talmadge JE: Evidence that intravenously derived murine pulmonary metastases can originate from the expansion of a single tumor cell. Cancer Res 46: 5167-5171, 1986.
6. Stackpole CW: Intrapulmonary spread of established B16 melanoma lung metastases and lung colonies. Invasion Metastasis 10: 267-280, 1990.
7. Okada T, Higuchi M, Takano M, Maruyama T and Osawa T: Anti-tumor efficacy of mouse spleen cells separated with Dolichos biflorus lectin (DBA) in experimental pulmonary metastasis of B16 melanoma cells. Br J Cancer 61: 241-249, 1990.
8. Esumi N, Fan D and Fidler IJ: Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 51: 4549-4556, 1991.
9. Okoshi H, Hakomori S, Nisar M, Zhoiu Q, Kimura S, Tashiro K and Igarashi Y: Cell membrane signalling as target in cancer therapy II: inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent aggregation. Cancer Res 51: 6019-6024, 1991.
10. + T cells clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol 146: 3235-3241, 1991.
11. Kjonniksen I, Hoifordt HK, Pihl A and Fodstad O: Different metastatic patterns of a human melanoma cell line in nude mice and rats: influence of microenvironment. J Natl Cancer Inst 83: 1020-1024, 1991.
12. Nierodzik MLR, Kajumo F and Karpatkin S: Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 52: 3267-3272, 1992.
13. Dyce M, Sharif SF and Whalen GF: Search for anti-metastatic therapy: effects of phenytoin on B16 melanoma metastasis. J Surg Oncol 49: 107-112, 1992.
14. Gersten DM, Moody D, Vieira WD, Law LW and Hearing VJ: Production of monoclonal antibodies against the B700 murine melanoma antigen and their antimetastatic properties. Biochim Biophys Acta 1138: 109-114, 1992.
15. Spremulli EN, Bogaars HA, Dexter DL, Matook GM, Jolly GA, Kuhn RE, Cummings FJ and Calabresi P: Nude mouse model of the melanosis syndrome. J Natl Cancer Inst 71: 933-939, 1983.
16. Nathanson SD, Haas GP, Mead MJ and Lee M: Spontaneous regional lymph node metastases of three variants of the B16 melanoma: relationship to primary tumor size and pulmonary metastases. J Surg Oncol 33: 41-45, 1986.
17. Hearing VJ, Gersten DM, Montague PM, Vieira WD, Galetto G and Law LW: Murine melanoma-specific tumor rejection activity elicited by a purified, melanoma-associated antigen. J Immunol 137: 379-384, 1986.
18. Shiohara T, Moellmann G, Jakobson K, Kuklinska E, Ruddle NH and Lerner AB: Antitumor activity of class II MHC antigen-restricted cloned autoreactive T cells. J Immunol 138: 1979-1986, 1987.
19. Shoemaker RH, Dykes DJ, Plowman J, Harrison SD, Griswoil DP, Abbott BJ, Mayo JG, Fodstad O and Boyd MR: Practical spontaneous metastasis model for in vivo therapeutic studies using a human melanoma. Cancer Res 51: 2837-2841, 1991.
20. Mori M, Yamaguchi K, Honda S, Nagasaki K, Ueda M, Abe O and Abe K: Cancer cachexia syndrome developed in nude mice bearing melanoma cell producing leukemia-inhibitory factor. Cancer Res 51: 6656-6659, 1991.
21. Stockey TR, Lin K, Sung C, Nagy JA, Tompkins RG, Dedrick RL, Dvorack HF and Yarmush ML: A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels. Cancer Res 52: 357-366, 1992.
22. Giavazzi R, Chirivi RGS, Garofalo A, Rambaldi A, Hemingway I, Pigott R and Gearing AJH: Soluble intercellular adhesion molecule I is released by human melanoma cells and is associated with tumor growth in nude mice. Cancer Res 52: 2628-2630, 1992.
23. + T cells by B7-transfected melanoma cells. Science 259: 368-370, 1993.
24. Shrayer D, Koness J, Kouttab N, Bogaars H, Hearing VJ, Gersten DM, Maizel A and Wanebo H: Preimmunization of mice with formalinized extracellular antigens of melanoma in combination with IL-2 and surgical resection increased survival and tumor control in metastatic melanoma model. J Surg Oncol 52: 142-149, 1993.
25. Shrayer D, Bogaars H, Hearing VJ, Maizel A and Wanebo H: Further characterization of a clinically relevant model of melanoma metastasis and an effective vaccine. Cancer Immunol Immunother 40: 277-282, 1995.
26. Gorodilova VV and Hollinshead A: Melanoma antigens that produce cell-mediated immune responses in melanoma patients: joint US-USSR study. Science 190: 391-392, 1975.
27. Ross AH, Cossu G, Herlyn M, Bell JR, Steplewski Z and Koprowski H: Isolation and chemical characterization of a melanoma-associated proteoglycan antigen. Arch Biochem Biophys 225: 370-383, 1983.
28. Lotan R, Lotan D and Deutsch V: Growth inhibition of murine melanoma cells by antibodies to a cell surface glycoprotein implicated in retinoic acid action. Cancer Res 47: 3152-3158, 1987.
29. Herlyn M, Rodeck U, Mancianti M, Cardillo FM, Lang A, Ross AH, Jambrosic J and Koprowski H: Expression of melanoma-associated antigens in rapidly dividing human melanocytes in culture. Cancer Res 47: 3057-3061, 1987.
30. Real FX, Furukawa KS, Mattes MJ, Gusik SA, Cordon-Cardo C, Oettgen HF, Old LJ and Lloyd KO: Class I (unique) tumor antigens of human melanoma: identification of unique and common epitopes on a 90-kDa glycoprotein. Proc Natl Acad Sci USA 85: 3965-3969, 1988.
31. Passaniti A and Hart GW: Metastasis-associated murine-melanoma cell surface galactosyltransferase: characterization of enzyme activity and identification of the major surface substrates. Cancer Res 50: 7261-7271, 1990.
32. Watanabe M, Sugimoto Y and Tsuruo T: Expression of a M 41,000 glycoprotein associated with thrombin-independent platelet aggregation in high metastatic variants of murine B16 melanoma. Cancer Res 50: 6657-6662, 1990.
33. Shockley TR, Mandeville JT, Tompkins RG and Yarmush ML: Equilibrium binding characteristics of monoclonal antibodies recognizing melanoma cell surface antigens. Hybridoma 9: 527-544, 1990.
34. Chattopadhyay P, Sneed D, Rosenberg J, Starkey J, Robertson N, Leonard J and Raychudhuri S: Monoclonal anti-idiotype antibodies. Cancer Res 51: 3183-3192, 1991.
35. Feyes V, Sikora LK, McGarry RC and Jerry LM: Human melanoma-associated antigen expression. Oncology 48: 58-64, 1991.
36. Demetrick DJ, Herlyn D, Tretiak M, Creasey D, Donoso LA, Vennegoor CJGM, Dixon WT and Jerry LM: ME491 melanoma-associated glycoprotein family: antigenic identity of ME491, NKI/C-3, neuroglandular antigen (NGA), and CD63 proteins. J Natl Cancer Inst 84: 422-429, 1992.
37. Nores GA, Dohi T, Tanigushi M and Hakomori S-I: Density-dependent recognition of cell surface GM3 by a certain antimelanoma antibody, and GM3 lactone as a possible immunogen. J Immunol 139: 3171-3176, 1987.
38. Livingston PO, Natoli EJ, Calves MJ, Stockert E, Oettgen HF and Old LJ: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84: 2911-2919, 1987.
39. Livingston PO, Ritter G, Srivastava P, Padavan M, Calves MJ, Oettgen HF and Old LJ: Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49: 7045-7050, 1989.
40. Bystryn J-C: Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma associated antigens. J Immunol 120: 96-101, 1978.
41. Bystryn J-C, Jacobsen S, Harris M, Roses D, Speyer J and Levin M: Preparation and characterization of a polyvalent human melanoma antigen vaccine. J Biol Resp Modif 5: 211-224, 1986.
42. Johnston D, Schachne JP and Bystryn J-C: Identification of immunogenic B16 melanoma-associated antigen. J Biol Resp Modif 6: 108-120, 1987.
43. Oratz R, Dugan M, Roses DF, Harris MN, Speyer JL, Hochster H, Weissman J, Henn M and Bystryn J-C: Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine. Cancer Res 51: 3643-3647, 1991.
44. McGee JMC, Lytle GH, Malnar KF, Price JA and Humphrey LJ: Melanoma tumor vaccine: five-year follow-up. J Surg Oncol 47: 233-238, 1991.
45. Wallack MK, Michaelides MC and Brada N: Reactivity to human melanoma lines in serums of patients undergoing treatment with vaccinia melanoma oncolysate. Amer Coll Surg XXXIV: 429-432, 1983.
46. Wallack MK, McNally K, Michaelides M, Bash J, Bartolucci A, Siegler H, Balch C and Wanebo H: A phase I/II SECSG pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO). Amer Surg 52: 148-151, 1986.
47. Berd D, Maguire HC, McCue P and Mastrangelo MJ: Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. J Clin Oncol 8: 1858-1867, 1990.
48. Elias EG, Tomazic VJ and Buda BS: Adjuvant immunotherapy in melanoma: a new approach. J Surg Oncol 50: 144-148, 1992.
49. Van der Bruggen P, Traversary C, Chomez P, Lurquin C, De Plaen E, van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
50. Rosenberg SA: Immunotherapy and gene therapy of cancer. Cancer Res 51 (Suppl): 5074-5079, 1991.
51. Graf LH Jr: Molecular cloning of genes that specify melanoma-associated antigens. In: Human Melanoma. Ferrone S (ed). Springer-Verlag, pp95-106, 1990.
52. Estin CD, Plowman GD, Rose TM and Brown JP: Characterization of p97, a human melanoma-associated antigen, and development of a recombinant vaccine for melanoma. In: Human Melanoma. Ferrone S (ed). Springer-Verlag, pp87-94, 1990.
53. Hayashibe K, Mishima Y and Ferrone S: Cloning and in vitro expression of a melanoma-associated antigen immunogenic in patients with melanoma. J Immunol 147: 1098-1104, 1991.
54. b transfection of B16 melanoma cells results in reduced tumori-genicity and metastatic competence. J Immunogenet 16: 291-298, 1989.
55. b gene in B16 cells correlates with suppression of liver metastases in triple immunodeficient mice. Cancer Res 52: 4036-4041, 1992.
56. Arlen M, Hollnshead A and Scherrer J: Immunity in malignant melanoma. In: Malignant Melanoma. Ariel IM (ed). Publ Div Prentice-Hall, Inc., pp129-141, 1981.
57. Bystryn J-C: Vaccine immunotherapy of melanoma. In: Human Melanoma. Ferrone S (ed). Springer-Verlag, pp513-530, 1990.
58. Oettgen HF, Livingston PO and Old LJ: Melanoma. In: Biologic Therapy of Cancer. De Vita VT, Hellerman S and Rosenberg SA (eds). JB Lippincott Company, 26.2: pp682-698, 1991.
59. Bitterman P, Hearing VJ and Gersten DM: Melanoma antigens as modified normal gene sequences. Life Sci 40: 2207-2213, 1987.
60. Gersten DM and Hearing VJ: Albuminoid molecules: a novel, variability-generating cell-surface receptor system? Med Hypotheses 30: 135-140, 1989.
61. Hearing VJ and Nicholson JM: Abnormal protein synthesis in malignant melanoma cells. Cancer Biochem Biophys 4: 59-63, 1980.
62. Farzaneh NK, Walden TL, Hearing VJ and Gersten DM: B700, a melanoma-specific antigen, catalyzes metabolism of prostaglandin E2. Int J Cancer 45: 104-108, 1990.
63. Hearing VJ, Vieira WD and Law LW: Malignant melanoma: cross-reacting (common) tumor rejection antigens. Int J Cancer 35: 403-409, 1985.
64. Gersten DM, Hearing VJ and Marchalonis JJ: Characterization of immunologically significant unique B16 melanoma proteins produced in vivo and in vitro. Proc Natl Acad Sci USA 78: 5109-5112, 1981.
65. Gersten DM, Phillips TM and Hearing VJ: Temporal synthesis and presentation of antigens by cultured B16 melanoma cells. Pigment Cell Res 1: 118-123, 1987.
66. Vlock DR, Hearing VJ and Gersten DM: Studies on the immunologic cross-reactivity of the B700 (67 kD) murine and MAA (66 kD) human melanoma antigen. Pigment Cell Res 5: 71, 1992.
67. Shrayer D, Koness J, Maizel A and Wanebo H: Induction of interleukin-2, natural killer cell activity and anti-melanoma antibodies resulting from immunization of mice with formalinized extracellular antigens (IECA) of murine melanoma. Melanoma Res 2: 47-56, 1992.
68. Shrayer D, Gersten DM, Koness J, Maizel A, Wanebo H and Hearing VJ: B700 antigen as a component of an antimelanoma vaccine: formalinized extracellular antigens. Pigment Cell Res 5: 107-112, 1992.
69. Hearing VJ, Gersten DM, Shrayer D and Law LW: Novel experimental approaches to melanoma diagnosis and treatment. J Dermatol 21: 860-869, 1994.
70. Abdel-Wahab Z, Dar MM, Hester D, Vervaert C, Gangavalli R, Darrow TL and Seiger HF: Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells. Cell Immunol 17: 246-254, 1996.
71. + cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system. Proc Natl Acad Sci USA 93: 10399-10404, 1996.
72. Thompson RC, Pardoll DM, Jaffee EM, Ewend MG, Tyler BM and Brem H: Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. J Immunother Emphasis Tumor Immunol 19: 405-413, 1996.
73. Ju DW, Cao X and Acres B: Active specific immunotherapy of pulmonary metastasis with vaccinia melanoma oncolysate prepared from granulocyte/macrophage-colony-stimulating-factor-gene-encoded vaccinia virus. J Cancer Res Clin Oncol 122: 716-722, 1996.
74. Schweighoffer T, Schmidt W, Buschle M and Birnsteiiel ML: Depletion of naive T cells of the peripheral lymph nodes abrogates systemic antitumor protection conferred by IL-2 secreting cancer vaccines. Gene Ther 3: 819-824, 1996.
75. Schmidt W, Maass G, Buschle M, Schweighoffer T, Berger M, Herbert E, Schilcher F and Birnstiel ML: Generation of effective cancer vaccines genetically engineered to secrete cytokines using adenovirus-enhanced transfection (AVET). Gene 190: 211-216, 1997.
76. Stidham KR, Ricci WM, Vervaert C, Abdel-Wahah Z, Seigler HF and Darrow TL: Modification of specific active immunization against murine melanoma using recombinant cytokines. Surg Oncol 5: 221-229, 1996.
77. Lipshy KA, Kostuchenko PJ, Hamad GG, Bland CE, Barrett SK and Bear HD: Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine-transduced melanoma. Ann Surg Oncol 4: 334-341, 1997.
78. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murinc granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543, 1993.
79. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinum thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
80. Chomczynski P: Reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15: 432-436, 1993.
81. Puntschart A, Jostarndt K, Hoppeler H and Billeter R: An efficient polymerase chain reaction approach for the quantitation of multiple RNAs in human tissue samples. PCR Meth 3: 232-238, 1994.
82. Tomita Y, Montague PM and Hearing VJ: Monoclonal antibody production to a B16 melanoma associated antigen. Int J Cancer 35: 543-547, 1985.
83. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R and Gilboa E: Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217-1224, 1990.
84. Gillis S, Ferm MM and Ou W: T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 120: 2027, 1978.
85. Muul LM, Spiess PJ, Director EP and Rosenberg SA: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138: 989-995, 1987.
86. Evans R and Duffy TM: Amplification of immune T lymphocyte function in situ: the identification of active components of the immunologic network during tumor rejection. J Immunol 135: 1498-1504, 1985.
87. De La Fuente M, Alonco MC, Solana R and Rena J: Macrophage and lymphocyte antibody-dependent cellular cytotoxicity in spontaneous leukemogenesis of AKR/J mice. Tumor Biol 10: 310-315, 1989.
88. Shiohara T, Ruddle NH, Horowittz M, Moellman GE and Lemer AB: Anti-tumor activity of class II MHC antigen-restricted cloned autoreactive T cells. 1. Destruction of B16 melanoma cells mediated bystander cytolysis in vitro. J Immunol 138: 1971-1978, 1987.
89. Fujiwara T, Sakagami K and Matsuoka: Application of an interleukin-2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases Cancer Res 50: 7003-7007, 1990.
90. Shrayer D, Kouttab N, Maizel A, Wanebo H, Hearing VJ and Gersten DM: Generation of cytotoxic antibodies to the B16 murine melanoma using a formalinized vaccine. Int J Cancer 53: 696-702, 1993.
91. Shrayer D, Koness J, Kouttab N, Bogaars H, Hearing VJ, Maizel A and Wanebo HJ: Antitumor effects of polyvalent and monovalent vaccines coupled with interleukin 2 in a metastatic melanoma model. Int J Oncol 6: 1121-1127, 1994.
92. Shrayer D, Park C-H, Kouttab N, Bogaars H, McInnis R, Paul SR, Maizel A, Hearing VJ and Wanebo HJ: Intrasplenic vaccination against experimental melanoma. Int J Oncol 9: 123-129, 1996.
93. Shrayer D, Bogaars H, Hearing VJ and Wanebo HJ: Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy. J Exp Ther Oncol 1: 126-133, 1996.
94. Stern AS, Podlaski FJ, Hulmes JD, Pan Y-C, Quinn PM, Wolitzky AG, Familetti PC, Stremlo DL, Truitt T, Cizzonite R and Gately MK: Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoid cells. Proc Natl Acad Sci USA 87: 6808-6812, 1990.
95. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Heweck RM, Kelleher K, Herrmann SH, Clark SC, Azzoni L, Chan SH, Trinchieri G and Perussia B: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146: 3074-3081, 1991.
96. Schoenhault DS, Chua AO, Wolinsky AG, Quinn PM, Dwyer CM, McComas W, Familetti PC, Galety MK and Gubler U: Cloning and expression of murine IL-12. J Immunol 148: 3433-3440, 1992.